Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioELife Corp. (LITH)
Seal Beach, CA, US
Engaged in the cannabinoid industry, BioELife Corp. provides a comprehensive selection of products. Their offerings span a variety of items such as adult gummies and tinctures (both available in combo formulations with chirorub), an intensive relief rub, standard tinctures, additional adult gummies, premium pre-rolled products, and flower. The company, established in 2006, was formerly known as US Lithium Corp. and underwent a name change to BioELife Corp. in March of 2020. Its operational base is located in Seal Beach, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-30.0% Q3'19: -196.2% (vs Q3'18)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'19: +1,263.9% (vs Q3'18)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.3% Q3'19: +81.3% (vs Q3'18)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-3.79× Q3'19: 0.00× (vs Q3'18)
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel C. | Legal Counsel | — | — |
| Michael Terpin | General Partner | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LITH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
